One of the key issues facing public healthcare is the global trend of an increasingly ageing
society which continues to present policy makers and caregivers with formidable healthcare …

At least 20 million hepatitis E virus (HEV) infections occur annually, with> 3 million
symptomatic cases and∼ 60,000 fatalities. Hepatitis E is generally self-limiting, with a case …

Current antiviral therapies, such as pegylated interferon-α and nucleos (t) ide analogues,
effectively improve the quality of life of patients with chronic hepatitis B. However, they can …

With more than 240 million people infected, hepatitis B virus (HBV) is a major health
concern. The inability to mimic the complexity of the liver using cell lines and regular primary …

Hepatitis B virus (HBV) remains a major medical problem affecting at least 257 million
chronically infected patients who are at risk of developing serious, frequently fatal liver …

The maintenance of terminally differentiated cells, especially hepatocytes, in vitro has
proven challenging. Here we demonstrated the long-term in vitro maintenance of primary …

Hepatitis B virus (HBV) is a highly contagious pathogen that afflicts over a third of the world's
population, resulting in close to a million deaths annually. The formation and persistence of …

Therapies against hepatitis B virus (HBV) have improved in recent decades; however, the
development of individualized treatments has been limited by the lack of individualized …

Chronic hepatitis B virus (HBV) infections result in 887,000 deaths annually. The central
challenge in curing HBV is eradication of the stable covalently closed circular DNA …

Background & Aims The persistence of covalently closed circular DNA (cccDNA) in infected
hepatocytes is the major barrier preventing viral eradication with existing therapies in …